Brand-name vs compounded
Hers vs Wellorithm: Brand-Name or Compounded? (2026)
Hers $149/mo, Wellorithm quotes after intake. What each 2026 program includes, what it omits, and which patient each one suits.
Published · Pricing as published in our provider dataset, synced · Editorial scores 9.8 and 7.5 out of 10
We may receive compensation when you click partner links. Rankings are based on research methodology, not sponsorship.
Wellorithm and Hers both promise a fast route to GLP-1 treatment without an office visit. What they promise afterward is where they separate.
Hers dispenses brand-name, FDA-approved finished medication. Wellorithm dispenses compounded medication prepared by a pharmacy rather than manufactured under an approved application. Those are different regulatory categories, and the price difference between them is the whole reason both business models exist.
Each program is read on its own published terms first, then against the other on the four things that decide satisfaction: price, predictability, formulary and access to a clinician. Where a figure is not published, that is stated rather than estimated.
The short answer
- Easier to price in advance
- Hers — Wegovy pill from $149/mo, injectable from $199/mo. The other side quotes after intake, so a like-for-like total is not available before you apply.
- FDA-approved medication
- Hers — FDA-approved Wegovy pill (oral semaglutide) and Wegovy injectable pen — a finished product the FDA has reviewed, rather than a compounded preparation.
- Fastest route to a first shipment
- Hers — Online intake with clinician review, then home delivery, no insurance required.
- Widest medication choice
- Hers — FDA-approved Wegovy pill (oral semaglutide) and Wegovy injectable pen.
Hers and Wellorithm, side by side
Scan the pricing rows first, then the medication row. Those two settle most of these decisions between them.
| Hers | Wellorithm | |
|---|---|---|
| Advertised price | Wegovy pill from $149/mo, injectable from $199/mo | Priced after the eligibility quiz |
| Rate after promotions | $149/mo | not published before intake |
| Pricing structure | Published rate per medication | Quoted only after intake |
| Medication | FDA-approved Wegovy pill (oral semaglutide) and Wegovy injectable pen | Compounded semaglutide and compounded tirzepatide |
| Support model | Provider check-ins included | No coaching program stated |
| Shipping | Home delivery, no insurance required | Medication shipped to your home |
| Price transparency | Published upfront | Quote only, after intake |
| Tirzepatide | Not published | Not published |
| Patient reviews | 6,200 | 3,240 |
| eRxDoctor score | 9.8/10 | 7.5/10 |
Hers vs Wellorithm on total cost, not entry price
Both providers lead with a number designed to get you through the intake. Here is what each one costs across a realistic course of treatment, on published pricing.
| Hers | Wellorithm | |
|---|---|---|
| First month | $149 | Not published |
| Months 2 onward | $149/mo | Not published |
| 6-month total | $894 | Not computable |
| 12-month total | $1,788 | Not computable |
| Best published plan | No multi-month discount published | No multi-month discount published |
A like-for-like annual total is not available for Wellorithm: pricing is not published; you receive a quote only after completing the intake quiz. Treat any comparison that quotes one as an estimate someone else has made for you.
Approved medication or compounded preparation
On Hers's side of the line sits FDA-approved Wegovy pill (oral semaglutide) and Wegovy injectable pen — product manufactured under an approved application, with the batch-to-batch consistency that approval requires.
Wellorithm works with compounded semaglutide and compounded tirzepatide. Compounding is what puts a lower price within reach; it also means no approval application stands behind the specific product you receive.
The honest framing is a trade, not a ranking. Compounded access is what has put GLP-1 treatment within reach of people whose insurance will not cover it; approved product is what removes a category of uncertainty about what is in the vial. Both of those are real.
How Hers works
Hers offers FDA-approved Wegovy® (brand-name semaglutide) with a personalized care team and ongoing dose check-ins, no compounded medications. What it is really selling here is brand-name Wegovy at a price that usually buys compounded medication elsewhere.
Getting started means online intake with clinician review, after which home delivery, no insurance required. Pricing runs on a published rate per medication basis, published upfront.
Ongoing care is personalized care team with ongoing dose check-ins, and the medication list runs to FDA-approved Wegovy pill (oral semaglutide) and Wegovy injectable pen.
Hers pros
- No insurance required
- FDA-approved brand-name Wegovy®, not a compounded product
- Personalized care team with ongoing dose check-ins
Hers cons
- No compounded/generic alternative offered
- Higher starting price than most compounded competitors
Against Wellorithm specifically, the trade you are making: there is no compounded tier to fall back on if the brand-name price stops working for you.
A closer look at Wellorithm
Take the 2-Minute Quiz to Check Your Eligibility Against Hers, that puts it in the position of the harder of the two to price in advance.
The process is 2-minute eligibility quiz, then medication shipped to your home. On money, expect quoted only after intake — quote only, after intake.
Behind the prescription sits virtual consultations with licensed clinicians. Available medication: compounded semaglutide and compounded tirzepatide.
Wellorithm pros
- Strong fit for patients in states with limited GLP-1 telehealth access
- No insurance pre-authorization required
- Fully virtual consultations with medication shipped to your home
- Both compounded semaglutide and tirzepatide available
Wellorithm cons
- Smaller, less-established platform with limited public reviews
- Pricing is not published, you only get a quote after completing the intake quiz
- Compounded medication only, no branded Ozempic, Wegovy, or Zepbound
Set beside Hers, the thing to weigh: a smaller platform with no published price and limited public review volume.
Who should choose Hers, and who should choose Wellorithm
Choose Hers if:
- you want an FDA-approved finished medication rather than a compounded preparation
- you want the full price in front of you before completing an intake
- you would get real value from brand-name Wegovy at a price that usually buys compounded medication elsewhere
- the level of clinical contact suits you: personalized care team with ongoing dose check-ins
Choose Wellorithm if:
- delivery works the way you want it to: medication shipped to your home
- the feature you would actually use: licensed clinicians in all 50 states, which matters in the states where GLP-1 telehealth coverage is thin
- you are in a state where GLP-1 telehealth coverage is patchy
- you want to start on their timeline: 2-minute eligibility quiz
What each one gives up
On price. Only Hers publishes a rate you can plan against (Wegovy pill from $149/mo, injectable from $199/mo). The other quotes after intake, which is a cost of a different kind: you cannot budget the year in advance.
On access. Hers advertises online intake with clinician review and home delivery, no insurance required; Wellorithm advertises 2-minute eligibility quiz and medication shipped to your home. Coverage differs too — not published against all 50 states — which decides the question before price does if you are in a restricted state.
On predictability. The pricing structures differ (published rate per medication versus quoted only after intake), and structure, not headline rate, determines the twelve-month bill.
On clinical contact. Hers provides personalized care team with ongoing dose check-ins. Wellorithm provides virtual consultations with licensed clinicians. Both are asynchronous-first services and neither replaces a physician who can examine you.
Evidence and regulatory status
It is worth separating the program from the pharmacology. What follows is true of the medication regardless of which of these two writes the prescription.
Weight regain after withdrawal is the documented pattern: the STEP 1 extension recorded participants returning to close to their starting weight a year after stopping, per Diabetes, Obesity and Metabolism.
STEP 1 recorded a mean 14.9% reduction in body weight over 68 weeks on weekly semaglutide, against 2.4% for placebo, per NEJM, STEP 1.
Neither platform's marketing changes any of that. It is the same evidence base whichever one takes your card.
Hers vs Wellorithm: common questions
Which is cheaper to start, Hers or Wellorithm?
Only Hers publishes a first-month figure (Wegovy pill from $149/mo, injectable from $199/mo). The other quotes after intake, so a starting-cost comparison is not available in advance.
How much does Wellorithm cost?
Pricing is not published; you receive a quote only after completing the intake quiz. That is the honest answer, and it is the main practical drawback next to Hers, which publishes Wegovy pill from $149/mo, injectable from $199/mo upfront. If you go through the intake, ask for the month-two and maintenance-dose prices in writing before paying for the first month.
Do Hers or Wellorithm take insurance?
Both run on a direct-pay basis: you pay the platform and it does not bill your insurer. Neither publishes HSA/FSA acceptance, so budget the full amount as out-of-pocket spending.
Which has more patient reviews, Hers or Wellorithm?
Hers, with 6,200 against 3,240. Ratings across this market cluster tightly, so volume is the more useful signal: it indicates how much operational load the platform has already absorbed, not how good the medication is.
Are Hers and Wellorithm legitimate?
Both are licensed telehealth platforms that route a prescription through a clinician review before anything is dispensed; neither sells medication without one. Hers operates on published rate per medication with pricing published upfront, Wellorithm on quoted only after intake, quote only, after intake. The meaningful due diligence is on the medication category and the terms, not on whether the platforms are real.
The verdict
Neither of these two publishes enough for a clean cost verdict, which is itself the finding. Hers leads on brand-name Wegovy at a price that usually buys compounded medication elsewhere; Wellorithm leads on licensed clinicians in all 50 states, which matters in the states where GLP-1 telehealth coverage is thin.
Before choosing either, get the maintenance-dose price in writing. Without it, any comparison — including this one — is working with half the information.
Whichever way you go, the medication is the same class of drug and the clinical questions belong to a clinician. What you are choosing here is a billing model and a support structure.
Keep comparing
- Hers vs TrimRxBrand-name vs compounded
- Shed vs HersPublished price vs quote-only
- Wellorithm vs He & She MDPublished price vs quote-only
- Wellorithm vs MaximusPublished price vs quote-only
- Ro.co vs NoviBrand-name vs compounded
- Ro.co vs Mochi HealthBrand-name vs compounded
See every provider in context on the weight loss rankings, or browse the full comparison index.
Disclaimers and methodology
Medical content is informational only and does not replace professional diagnosis, treatment, or emergency care.
Some links are affiliate links and may generate commission at no extra cost to you.
Pricing reflects what each provider published as of the sync date above and changes frequently; confirm the current rate, and the rate at your maintenance dose, before you pay. Six- and twelve-month totals are calculated from those published rates and exclude anything a provider bills separately.
eRxDoctor is an independent publisher. It is not a medical provider, is not affiliated with or endorsed by Hers or Wellorithm, and does not sell treatment. Read our ranking methodology.